SecBot SecBot
PRESS-RELEASE ·Filed Jul 13, 2026

MESO

Mesoblast Limited
NEUTRAL
Impact 5/10
Horizonmonths Processed4mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

The enrollment completion removes a key timeline risk, but the stock remains binary on trial results due in ~1 year. Monitor for any interim analyses or regulatory updates.

DirectionNeutral
Confidencehigh
Horizonmonths

rexlemestrocel-L

▲ Bullish Named in this press release
Impact
Phase
Phase 3 / Filed BLA
Time to market
LVAD/heart failure BLA now under FDA review with modular review requested — no PDUFA date set yet (potentially 2027 if accepted). CLBP indication likely 2028 at earliest (topline mid-2027, BLA Q3 2027, FDA action 2028).
Next catalyst
None dated

What to watchMesoblast just filed a BLA for rexlemestrocel-L in LVAD/heart failure, the next catalyst is FDA acceptance and a PDUFA date. Meanwhile, the much larger CLBP opportunity (7M+ US patients, non-opioid approach) is advancing with Phase 3 enrollment complete and topline due mid-2027. The company already generates real revenue from Ryoncil (~$110-120M FY2026 guidance), de-risking the story vs. pre-revenue biotechs. Monitor (1) FDA's action on the LVAD BLA modular review, (2) CLBP Phase 3 topline in mid-2027, and (3) Ryoncil revenue growth trajectory.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$16.74
T+0 close · Jul 13, 2026 · via day close
Latest settled
−16.73%
T+60 · $13.94
Vs SPY
−20.10%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 14 $16.74entry
  2. T+1 · 4mo ago +8.96%α +8.56% · $18.24
  3. T+5 · 4mo ago −0.66%α +0.64% · $16.63
  4. T+20 · 3mo ago +1.08%α −1.42% · $16.92
  5. T+60 · 6w ago −16.73%α −20.10% · $13.94
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Mesoblast announced completion of enrollment (at least 300 patients) in its pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain associated with degenerative disc disease. This milestone de-risks the trial timeline, but results are not expected until mid-2027, leaving significant binary risk. The stock may see a modest positive reaction, but the lack of efficacy data limits the near-term catalyst.

Key Facts

  • Enrollment target of at least 300 patients achieved in MSB-DR004 Phase 3 trial of rexlemestrocel-L for chronic low back pain (CLBP) associated with degenerative disc disease.
  • Top-line results expected in mid-CY2027 after the last patient completes 12 months follow-up.
  • Rexlemestrocel-L has FDA Regenerative Medicine Advanced Therapy (RMAT) designation, providing eligibility for priority review and rolling BLA review.
  • Company estimates peak year revenue potential of >$10 billion with single-digit market penetration, though this is forward-looking and not supported by current data.

Financial Impact

No financial data in this press release. Potential peak revenue >$10B cited by company, but this is a forward-looking estimate and not a hard financial figure.

Risk Factors

  • Trial may fail to meet primary endpoint, leading to significant downside.
  • Regulatory delays or CMC issues could push BLA filing and approval timeline.
  • Competing therapies or changes in standard of care could reduce commercial potential.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3326541

Track record

25 reports on MESO

Performance horizon

7 of 15 bullish or bearish reports moved the stock their way by T+1. Best: +24.95% at T+20 after the Jul 30, 2026 report. 10 of 15 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Neutral 2/10 Entry $13.25 Now $12.45 −6.04% settles Nov 17
  2. Nov 10, 20266d ago 6-K Neutral 3/10 Entry $13.65 to $13.10 Now $12.45 −8.79% ▼ −4.03% −3.68% vs SPY
  3. Nov 2, 202614d ago 6-K Neutral 2/10 Entry $14.77 to $14.29 Now $12.45 −15.71% ▼ −3.25% −4.90% vs SPY
  4. Oct 29, 202618d ago 6-K Bullish 6/10 No price data
  5. Oct 28, 202619d ago Press Release Bullish 6/10 Entry $15.67 to $15.16 Now $12.45 −20.55% ▼ −3.25% −1.48% vs SPY
  6. Oct 15, 20264w ago 6-K Bullish 6/10 Entry $13.28 to $11.95 Now $12.45 −6.25% ▼ −10.02% −10.44% vs SPY
  7. Oct 15, 20264w ago 6-K Neutral 2/10 Entry $13.95 to $13.28 Now $12.45 −10.75% ▼ −4.80% −3.70% vs SPY
  8. Oct 13, 20264w ago 6-K Mixed 6/10 Entry $13.90 to $13.79 Now $12.45 −10.40% ▼ −0.76% +0.33% vs SPY
  9. Sep 23, 20267w ago 6-K Neutral 3/10 Entry $15.48 to $15.12 Now $12.45 −19.57% ▼ −2.33% −2.87% vs SPY
  10. Aug 27, 202611w ago 20-F Bullish 6/10 Entry $18.18 to $17.44 Now $12.45 −31.52% ▼ −4.07% −3.84% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 13, 2026